Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

10.78USD
20 Aug 2019
Change (% chg)

-- (--)
Prev Close
$10.78
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
328,573
52-wk High
$25.15
52-wk Low
$6.81

Select another date:

Tue, Aug 6 2019

Amag's female libido injectable therapy to sell at $899

Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

UPDATE 1-Amag's female libido injectable therapy to sell at $899

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD).

Amag's female libido injectable therapy to sell at $899

Aug 6 Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for the condition.

FDA approves drug for loss of sexual desire in women

The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".

UPDATE 2-FDA approves drug for loss of sexual desire in women

June 21 The U.S. drug regulator on Friday approved Palatin Technologies and Amag Pharmaceuticals' drug to restore sexual desire in premenopausal women, the latest attempt to come up with a therapy that some have dubbed as "female Viagra".

FDA approves drug for loss of female sexual desire

June 21 The U.S. Food and Drug Administration on Friday approved Palatin Technologies Inc and Amag Pharmaceuticals Inc's drug to restore sexual desire in premenopausal women, Amag said.

Select another date: